Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The objective of this single-dose, open-label, randomized, two-treatment, two-period
crossover study was to compare the relative bioavailability of a test formulation of KADIAN
(2 x 10 mg) capsules manufactured by Alpharma Inc. to an equivalent oral dose of the
commercially available reference product, KADIAN (1 x 20 mg)capsules manufactured by Alpharma
Branded Products Inc. following an overnight fast of at least 10 hours.